Brian Greene Tells LMU Graduates: Embrace Your Moment in the Cosmos with Curiosity and Gratitude
Addressing a rapt crowd on LMU's sun-filled Westchester campus, the best-selling author told graduates "we have each won the most improbable cosmic lottery." See the press kit with images and Greene's commencement video HERE.
"Think about how utterly unlikely it is that you exist," Greene said. "Think about the nearly infinite collection of quantum processes stretching from The Big Bang until today … yet against those astounding odds – for a brief moment of time you exist, as do I."
Drawing on discoveries from Albert Einstein to Stephen Hawking and Carl Sagan to Edwin Hubble, Greene traced for students and attendees the arc of scientific discovery allowing us to better understand our place in the universe, and the phenomenon of our capacity to live, comprehend, and connect with one another. Greene also noted the contributions of Jesuit-educated Catholic priest Georges Lemaître, who "used Einstein's math to catch a glimpse of the possibility that space might be expanding," an idea widely rejected at the time, only to be established a few years later.
"We can think about the past. We can imagine the future. We can take in the universe, mind and body, with reasoning and emotion allowing us to figure out astonishing things, like how stars shine and light travels, how black holes form and time elapses, allowing for creative achievements … all created by minds like yours, like mine, and that …most certainly will continue to create great beauty, to illuminate great mystery, to experience great wonder."
This phenomenon of human existence, Greene concluded, "should give us all a deep sense of connection. A kind of cosmic communion, and a sense that I can summarize with one word: gratitude."
"Gratitude for being a small transient part of this wondrous unfolding, gratitude for our capacity to come together in groups that, at their best, allow us to each realize our potential, gratitude for our capacity for courage like that of George Lemaître, to stand up to authority, to not accept easy answers, and when necessary to fight for what we believe in. Gratitude that is for human existence, for fragile, delicate, difficult, challenging, painful, exhausting, beautiful, exquisite, transcendent, human existence, however brief, however evanescent, however fleeting."
Greene is a lifelong learner committed to intellectual inquiry, educational access, and academic excellence. Described by The Washington Post as "the single best explainer of abstruse concepts in the world today," he is the author of four acclaimed books that have collectively sold millions of copies worldwide. His latest best-selling release, "Until the End of Time," which explores the cosmos and our quest to understand it, was named one of the "100 Notable Books of 2020" by The New York Times.
Greene's books have been adapted into two Emmy and Peabody Award-winning NOVA miniseries, both of which he hosted. With journalist Tracy Day, he co-founded the World Science Festival, whose flagship events in New York and Australia have reached an audience of more than two million people, and more than 250 million people online. Greene has appeared on "The Late Show with Stephen Colbert," played himself in an episode of "The Big Bang Theory," and made cameo appearances in films including "Frequency," "Maze," and "The Last Mimzy." A Harvard graduate and a Rhodes Scholar, he serves as director of Columbia University's Center for Theoretical Physics.
Nearly 2,900 LMU undergraduate, graduate, and law students participated in weekend commencement celebrations, which began Saturday with Ahmir "Questlove" Thompson addressing the undergraduate commencement ceremony.
ABOUT LOYOLA MARYMOUNT UNIVERSITY
Loyola Marymount University is one of the nation's top-ranked Catholic universities, recognized by U.S. News & World Report among the top 50 private and top five Jesuit institutions in the country, and among California's top six private schools. Founded in 1911 and rooted in the Catholic, Jesuit, and Marymount traditions, LMU enrolls 7,100 undergraduates and 3,000 graduate and law students across seven colleges and schools. The university offers 56 undergraduate majors, 57 minors, 43 master's degree programs, three doctorate programs, and 12 credential/authorization programs. With top-ranked programs in law, film and television, entrepreneurship, business, and the arts, LMU is embedded in the creative, cultural, and economic life of Los Angeles. The university generates $1.4 billion in annual economic impact. A proud member of the West Coast Conference, LMU fields 14 NCAA Division I teams and competes with purpose, pride, and integrity.
LMU news and events are found at: www.lmu.edu/news.
View original content to download multimedia:https://www.prnewswire.com/news-releases/brian-greene-tells-lmu-graduates-embrace-your-moment-in-the-cosmos-with-curiosity-and-gratitude-302458502.html
SOURCE Loyola Marymount University
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Precision Era to Redefine Treatment, Drive $450B Economic Investment and Change Lives Across Asia Pacific
SINGAPORE, July 22, 2025 /PRNewswire/ -- The Precision Era of medicine is arriving in Asia Pacific, driven by the arrival of a critical mass of innovative therapies that will redefine treatment, attract investment and improve lives, a new expert-driven report finds. Released today, 'On the Cusp of a Cure' White Paper examines Asia Pacific's readiness for the Precision Era – the current, transformative period where generically prescribed and regularly administered treatments are increasingly giving way to potentially curative therapies tailored to individuals and their disease. Treatments called precision therapies. Across the four markets over the next 10 years, the new research by L.E.K. Consulting and an advisory committee of 16 Asia Pacific experts using a proprietary 'whole system benefits modelling' approach found that the Precision Era has the potential to: Drive direct economic investment of approximately USD 450 billion.[i] Create almost 1.2 million highly skilled jobs[i] in R&D, advanced manufacturing and biotechnology. Drive USD1.615 trillion in broader[i], indirect economic benefit via a multiplier effect across adjacent industries. Save healthcare systems across the four markets USD 39 billion[i], alleviating intense pressure on resources. Increase workforce participation for 24 million patients and caregivers by improving their ability to return or stay in work.[i] "The Precision Era is being driven by the arrival of a critical mass of some 4,000 innovative cell and gene therapies that will redefine treatment, attract investment and improve lives. Never before have we had such a clear view of the huge potential that this new era holds for Asia-Pacific. Healthcare systems stand to save billions, and patients could potentially live healthier for longer. The broader economic impact of this new era medicine is equivalent to South Korea's annual GDP, and the potential for new jobs greater than the entire population of Adelaide," said Stephanie Newey, Managing Partner, Head of L.E.K. Consulting Australia. Precision therapies put us on the cusp of a cure The 'On the Cusp of a Cure' research assessed data from more than 1,000 clinical trials across four novel technologies – gene therapies, targeted antibody therapies, drug-device combination therapies, and diagnostic technologies. These precision therapies are considered part of the Precision Era because they provide enhanced health benefits through a more tailored approach, represent a paradigm shift to how care has been provided previously and are the focus of significant research and investment. Critically, some experts suggest we may be on the cusp of a cure for diseases that have previously been considered incurable and represent Asia-Pacific's most pressing health challenges, such as many cancers and genetic disorders. "Asia disproportionately carries the largest cancer and rare disease burden in the world. It shoulders nearly half of all global cancer incidence[ii] and is home to 258 million people who are living with rare diseases[iii]. Worse still, these numbers are only expected to grow, fuelling calls for sustainable, scalable and effective solutions. Precision therapies are stepping forward to meet this critical need and represent a new standard of care for many of Asia-Pacific's health challenges," said Professor Baorong Yu, from the University of International Business and Economics in China. One of the most groundbreaking examples of these treatments is chimeric antigen receptor T-cell (CAR-T) therapy that modifies the body's own T cells (a type of white blood cell) to target and destroy cancer cells[iv]. It is commonly used in the treatment of blood cancers, which has a 50% survival rate for over a third of patients. Currently, these patients are mostly treated through chemotherapy and radiotherapy, but many do not respond or will relapse. "With increased access to innovative treatments such as CAR-T therapy, particularly earlier in treatment regimes, patients could live longer with a better quality of life," said Naomi Sakurai, Advisory Committee member and Founder and CEO, Cancer Solutions. "Rather than going through multiple rounds of chemo, they would have a therapy tailored specifically to their condition. These precision treatments are now offering hope by potentially curing once-incurable diseases and giving people the priceless gift of more time with their loved ones." What's holding back the adoption of precision therapies? The Precision Era brings fundamental change to the way disease is approached and how patients are treated, and requires an equivalent rethink from regulators and policymakers. While each market has its own, unique policy environment, 'On the Cusp of a Cure' series found that Australia, China, Japan, and South Korea all exhibit similar barriers to precision therapy adoption. Rules remain unclear for evaluating the reimbursement of new precision therapies, there is limited awareness among patients and doctors about these treatments, and better healthcare infrastructure is needed to support access. The 'On the Cusp of a Cure' research presents a number of regional solutions to unlock the potential benefits of precision therapies: Establish streamlined regulatory and reimbursement pathways specifically tailored for these treatments Increase education for providers, patients, and the community to enhance understanding of the Precision Era Enhance public-private collaboration to foster innovation and equitable access to precision therapies. Improve access and affordability through pricing strategies, reimbursement frameworks, and insurance initiatives for treatments and diagnostics alike. Through clinical guidelines and knowledge sharing, empower HCPs to make informed decisions about precision therapies, and assist patients in complex treatment paths. By backing local industry investments in therapies and diagnostics, and nurturing expertise, joint efforts can drive sustainable progress towards transformative innovations. "With this new era of precision therapies, we stand at the threshold of transforming healthcare across Asia-Pacific," said Sakurai. "But for the full potential of these medicines to materialise, regulatory systems as well as knowledge and infrastructure must keep up. The goal of precision therapies is to ensure the right patient, right timing, right treatment and right dose. We all have a role to play, including policymakers, healthcare professionals, and healthcare industry leaders, to remove barriers for patients to these potentially life-changing therapies." "On the Cusp of a Cure White Paper Asia Pacific Series is made up of four local market white papers evaluating barriers to precision therapy adoption, providing recommendations for improvement, and assessing the value of widespread adoption in Australia, China, Japan, and Korea. Notes to Editor: On the Cusp of a Cure White Paper Series and Advisory Committee Members The On the Cusp of a Cure whitepaper series was supported by an advisory committee of 16 pre-eminent regional experts in precision medicine, economic and health policy, and patient experience across Australia, China, Japan and Korea. It was also sponsored by Johnson & Johnson. Australia China South Korea Japan David Thomas, Chief Scientific Officer, Omico Jaala Pulford, Chair of the Board, MTPConnect Christine Cockburn, CEO, Rare Cancers Australia Baorong Yu, Professor and market access key opinion leader, University of International Business and Economics Andy Mok, Head of China, Guardant Health Kevin Huang, Founder and president, China Organization for Rare Disorders (CORD) Caicun Zhou, Professor and lung cancer key opinion leader, School of Medicine, Tongji University Paul Lee, Former GM, Gilead Sciences Korea Jin-Ah Kim, Advocate for rare diseases, Seoul National University Hospital, Department of Genomic Medicine, Rare Disease Centre Prof Jeonghoon Ahn, Professor of Health Convergence, Ewha University Teruyuki Katori, Representative Director, Special Appointed Professor, Future Institute Wolong, General Incorporated Association Graduate School of Social Sciences, University of Hyogo Daisuke Sato, Professor. Fujita Health university Manabu Muto, Professor, Kyoto University Graduate School of Medicine Masahiro Miyake, Professor, Kyoto University Hospital Naomi Sakurai, Founder and CEO, Cancer Solutions Keisuke Shimizu, Leader, Lung cancer HER2 "HER HER" About L.E.K. Consulting We're L.E.K. Consulting, a global strategy consultancy working with business leaders to seize competitive advantage and amplify growth. Our insights are catalysts that reshape the trajectory of our clients' businesses, uncovering opportunities and empowering them to master their moments of truth. Since 1983, our worldwide practice — spanning the Americas, Europe, Middle East and Asia-Pacific — has guided leaders across all industries from global corporations to emerging entrepreneurial businesses and private equity investors. Looking for more? Visit [i] L.E.K Consulting. On the Cusp of a Cure 2025. [ii] Huang J, Ngai CH, Deng Y, Tin MS, Lok V, Zhang L, Yuan J, Xu W, Zheng ZJ, Wong MCS. Cancer Incidence and Mortality in Asian Countries: A Trend Analysis. Cancer Control. 2022 Jan-Dec;29:10732748221095955. doi: 10.1177/10732748221095955. PMID: 35770775; PMCID: PMC9252010. [iii] IQVIA. Rare Diseases in APAC: The Unmet Potential. Available from Accessed April 2025. [iv] American Cancer Society. CAR T-cell therapy and Its Side-effects. Available from View original content: SOURCE L.E.K Consulting
Yahoo
5 days ago
- Yahoo
DNAKE Emerges as a Global Innovator in Brain-Computer Interface Technology
XIAMEN, China, July 18, 2025 /PRNewswire/ -- Brain-Computer Interface (BCI) technology is redefining human-machine interaction by establishing direct communication between the brain and external devices. This transformative innovation is driving profound societal impact across industries: revolutionizing neurological disease treatment (e.g., epilepsy, Parkinson's, and depression), enhancing educational outcomes through improved focus, and enabling seamless industrial human-robot collaboration. With aging populations and rising neurological disorders worldwide, BCI's healthcare applications are experiencing explosive demand. According to IMARC Group, the global BCI market reached $1.74 billion in 2022 and is projected to hit $3.3 billion by 2027. In this rapidly evolving field, DNAKE is establishing itself as a rising force through cutting-edge R&D and global vision. Technology Leadership & Standardization As a key driver of BCI advancement, DNAKE has forged strategic partnerships with elite research institutions like the CAS Key Laboratory of Brain Function and Diseases, Xiamen University's Brain Cognition & Intelligent Computing Lab, etc. These collaborations underscore its dual strengths: proprietary innovation and integration of top-tier academic resources. DNAKE holds pivotal roles in the BCI Industry Alliance and China Communications Standards Association, actively co-authoring technical standards such as "EEG-Based Attention Monitoring Systems: Technical Requirements and Testing Methods." This standardization expertise positions DNAKE to extend its influence into global markets, where consistent technical benchmarks are critical for adoption. Breakthrough Innovations DNAKE's BCI team recently published groundbreaking research in the Annals of the New York Academy of Sciences, solving a critical industry challenge: environmental adaptability. Their innovative "Human-AI Multi-agent Copilot" system merges EEG signal decoding with deep reinforcement learning AI, enabling devices to interpret user commands while autonomously responding to environmental changes—a leap from one-directional BCI systems to true interactive intelligence. In sleep health, Dr. Phang's team also developed a Multiscale Temporal Convolutional Neural Network (MTCNN) algorithm in the Journal of Neural Engineering that achieves 88.24% accuracy in sleep-stage classification—a 23% improvement over consumer-grade headbands (Miller et al., 2022). This approach sets new paradigms for EEG signal analysis. R&D Commitment DNAKE's 300+ member R&D team includes specialized BCI engineers, with 2024 R&D investment spiking to 11% of revenue. A dedicated $18 million BCI Technology Center will accelerate project commercialization. Strategic Vision Aligned with its "Innovation-Driven Transformation" strategy, DNAKE is pivoting toward digital health ecosystems while strengthening its smart community and hospital solutions. "In BCI, Chinese innovators compete on equal footing globally," notes DNAKE. "Through autonomous R&D and international collaboration, we're poised to shape BCI's future." About DNAKE DNAKE (Xiamen) Intelligent Technology Co., Ltd. is a global leader in smart intercom and home automation solutions. Since 2005, we've delivered innovative, high-quality products—including IP intercoms, cloud platforms, smart sensors, and wireless doorbells—to over 12.6 million households worldwide. Combining cutting-edge technology with customer-focused design, DNAKE provides reliable, scalable solutions for both residential and commercial needs. View original content: SOURCE DNAKE (Xiamen) Intelligent Technology Co., Ltd.
Yahoo
6 days ago
- Yahoo
EBSCO Information Services Introduces Africa Studies Source to Expand Global Scholarly Impact
~ Extensive Collection of Full-text Magazines and Journals for Africa Studies ~ IPSWICH, Mass., July 17, 2025 /PRNewswire-PRWeb/ -- Researchers across the globe looking for an authoritative resource for Africa studies will benefit from the release of Africa Studies Source from EBSCO Information Services (EBSCO). Africa Studies Source includes a vast array of scholarly full-text journals and magazines, offering detailed insights into the history, culture, politics, education, and ongoing medical and scientific research that define the African continent. Africa Studies Source offers researchers access to more than 656 magazines and journals, including 614 peer-reviewed journals. Researchers gain valuable insights from international and regional journals, all authored by leading experts in various fields. The unique resource provides coverage of a wide array of subjects including the African diaspora, African history and politics, agriculture, business and industry, cultural traditions, colonialism & human rights, economic development & globalization, education, environmental issues, foreign relations, government & politics, health & medicine, religion, and science & technology. EBSCO Information Services Senior Vice President of Research Databases Sara Earley says the new resource empowers scholars to explore the evolving narratives shaping the continent of Africa. "By providing access to a vast collection of scholarly journals, the database supports the advancement of research on Africa. Africa Studies Source is invaluable for researchers seeking in-depth insights into the continent's ongoing developments." The launch of Africa Studies Source demonstrates EBSCO's ongoing dedication to advancing global academic research with the addition of another Cultural and Area Studies resource. For more information, visit: Africa Studies Source. About EBSCO Information Services EBSCO Information Services (EBSCO) is a leading provider of online research content and cutting-edge search technologies serving libraries, healthcare and medical institutions, corporations, and government agencies worldwide. As an AI-enabled services leader, EBSCO offers comprehensive solutions from research, acquisition management, subscription services and discovery services to clinical decision support and patient care, learning, and research and development, EBSCO provides institutions with access to content and resources to serve the information and workflow needs of their users and organizations. Our commitment to AI-driven innovation positions EBSCO at the forefront of the industry, enabling us to meet the evolving needs of the information services landscape. For more information, visit the EBSCO website at: Visit our blog at EBSCOpost or follow us on X, Facebook, LinkedIn and Instagram. For more information, please contact: Karena Donnelly Sr Communications Specialist kdonnelly@ Media Contact Karena Donnelly, EBSCO Information Services, 9783566500, kdonnelly@ View original content to download multimedia: SOURCE EBSCO Information Services Sign in to access your portfolio